论文部分内容阅读
目的评价ESHAP(PDD,VPl6,Ara-C,甲泼尼龙)方案治疗难治性非霍奇金淋巴瘤近期疗效及不良反应观察。方法 14例难治性非霍奇金淋巴瘤患者行ESHAP方案化疗3周期。每3周重复,每例均应用3个疗程。结果 CR 6例,PR 3例,SD 3例,PD 2例.有效率(CR+PR)64.2%。不良反应主要为骨髓抑制、血糖升高。白细胞减少57%,血小板减少44%;28%患者出现血糖升高。白细胞、血小板经G-CSF及输注血小板后恢复正常;血糖应用胰岛素控制。结论 ESHAP方案治疗复发难治性非霍奇金淋巴瘤疗效肯定,不良反应可以耐受。
Objective To evaluate the short-term efficacy and adverse reactions of ESHAP (PDD, VP16, Ara-C, methylprednisolone) regimen in the treatment of refractory non-Hodgkin’s lymphoma. Methods Fourteen patients with refractory non-Hodgkin’s lymphoma underwent ESHAP regimen for 3 cycles. Repeat every 3 weeks, each application of 3 courses. Results 6 cases of CR, 3 cases of PR, 3 cases of SD and 2 cases of PD, the effective rate (CR + PR) was 64.2%. Adverse reactions mainly bone marrow suppression, elevated blood sugar. 57% of leukopenia, thrombocytopenia 44%; 28% of patients with elevated blood sugar. Leukocytes, platelets after G-CSF and platelet transfusion returned to normal; blood glucose insulin control. Conclusion The ESHAP regimen is effective in treating recurrent refractory non-Hodgkin’s lymphoma. The adverse reactions can be tolerated.